News Content
Its primary indication is **childhood growth hormone resistance-related diseases**, such as Laron syndrome (primary growth hormone insensitivity syndrome). These children, due to growth hormone receptor defects, cannot utilize their own or exogenous growth hormone to promote growth. IGF1-LR3 can directly act on growth plate chondrocytes, activating proliferation pathways. Clinical data show that daily subcutaneous injection of 0.04-0.08 mg/kg for 12 months can result in an annual height increase of 8-10 cm, far exceeding traditional treatment regimens, and can also improve bone density and muscle development.https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-igf1-lr3-1mg.html
In adult treatment settings, it can be used to intervene in tissue repair after severe burns. Burn patients often experience insufficient IGF-1 synthesis due to inflammatory responses, leading to delayed wound healing. Supplementing with IGF1-LR3 can accelerate epithelial cell proliferation, shortening the healing time of deep second-degree burns by 20%-30%. Furthermore, it has shown neuroprotective potential in clinical trials for neurodegenerative diseases (such as ALS), delaying motor neuron apoptosis, but it has not yet been officially approved for use.
It is important to note that IGF1-LR3 is a prescription drug, and misuse may cause risks such as hypoglycemia and joint hyperplasia. It is also listed as a prohibited substance by sports organizations. Endocrinologists emphasize: "Its therapeutic value must be based on accurate diagnosis and is only applicable to specific diseases with abnormal growth hormone pathways; it is by no means a 'repair agent' that can be used indiscriminately."

